# Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

> **NCT06254911** · PHASE2 · SUSPENDED · sponsor: **Emory University** · enrollment: 20 (estimated)

## Conditions studied

- Oropharynx Cancer, Stage I

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **PROCEDURE:** Transoral Surgery with cervical lymphadenctomy (neck dissection)
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT06254911
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-10-27
- **Primary completion:** 2026-12-16
- **Final completion:** 2026-12-16
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Institutional Review
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06254911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06254911, "Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06254911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*